RNA
Avidity Biosciences Inc (RNA)
Healthcare • NASDAQ • $13.20-2.08%
- Symbol
- RNA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $13.20
- Daily Change
- -2.08%
- Market Cap
- $219.64M
- Trailing P/E
- N/A
- Forward P/E
- -1.59
- 52W High
- $16.77
- 52W Low
- $11.13
- Analyst Target
- $25.00
- Dividend Yield
- N/A
- Beta
- N/A
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Company websiteResearch RNA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.